Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
OMG CRISPR/Cas9 KO Plasmid (h): sc-406746
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- OMG CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the OMG genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: OMG Antibody (E-8): sc-271704
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
OMG CRISPR/Cas9 KO Plasmid (h) | sc-406746 | 20 µg | $397.00 |
Overview
OMG (osteoglycin) encodes a secreted small leucine-rich proteoglycan that participates in extracellular matrix organization and collagen fibrillogenesis, influencing tissue biomechanics and cell–matrix signaling. By modulating matrix architecture, OMG can impact integrin-linked pathways and growth factor availability that shape cell adhesion, migration, and differentiation programs. Altered extracellular matrix remodeling involving OMG has been investigated in contexts such as fibrosis, cardiovascular remodeling, and tumor microenvironment biology, where stromal composition can affect disease-associated phenotypes. These features make OMG a useful target for studying how matrix components regulate cellular behavior and intercellular communication in human systems.
OMG CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the OMG gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the OMG together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the OMG open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish OMG protein expression.
This CRISPR knockout system enables efficient generation of OMG-deficient cell models for investigation of OMG signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting OMG exon(s) critical for OMG function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple OMG genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by OMG CRISPR/Cas9 KO Plasmid (h) and OMG CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the OMG locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by OMG HDR Plasmid (h) and OMG HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by OMG homology arms to support homology-directed repair at defined OMG target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.